Literature DB >> 26016462

Model for end-stage liver disease score and MELD exceptions: 15 years later.

Sumeet K Asrani1, Patrick S Kamath.   

Abstract

The model for end-stage liver disease (MELD) score has been used as an objective scale of disease severity for management of patients with end-stage liver disease; it currently serves as the basis of an urgency-based organ-allocation policy in several countries. Implementation of the MELD score led to a reduction in waiting-list registration and waiting-list mortality and an increase in the number of deceased-donor transplants without adversely affecting long-term outcomes after liver transplantation (LT). The MELD score has been used for management of non-transplant patients with chronic liver disease. MELD exceptions serve as a mechanism to advance the needs of subsets of patients with liver disease not adequately addressed by MELD-based organ allocation. Several models have been proposed to refine and improve the MELD score as the environment within which it operates continues to evolve toward transplantation for sicker patients. The MELD score continues to serve and be used as a template to improve upon as an objective gauge of disease severity and as a metric enabling optimization of allocation of scarce donor organs for LT.

Entities:  

Mesh:

Year:  2015        PMID: 26016462     DOI: 10.1007/s12072-015-9631-3

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  84 in total

1.  Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy.

Authors:  R B Freeman; E B Edwards
Journal:  Liver Transpl       Date:  2000-09       Impact factor: 5.799

2.  Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation.

Authors:  Connie L Davis
Journal:  Liver Transpl       Date:  2006-05       Impact factor: 5.799

3.  Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?

Authors:  T A Gonwa; M A McBride; K Anderson; M L Mai; H Wadei; N Ahsan
Journal:  Am J Transplant       Date:  2006-08-25       Impact factor: 8.086

4.  Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.

Authors:  Elizabeth A Pomfret; Kenneth Washburn; Christoph Wald; Michael A Nalesnik; David Douglas; Mark Russo; John Roberts; David J Reich; Myron E Schwartz; Luis Mieles; Fred T Lee; Sander Florman; Francis Yao; Ann Harper; Erick Edwards; Richard Freeman; John Lake
Journal:  Liver Transpl       Date:  2010-03       Impact factor: 5.799

5.  Sex-based disparities in liver transplant rates in the United States.

Authors:  A K Mathur; D E Schaubel; Qi Gong; M K Guidinger; R M Merion
Journal:  Am J Transplant       Date:  2011-07       Impact factor: 8.086

6.  Risk factors for mortality after surgery in patients with cirrhosis.

Authors:  Swee H Teh; David M Nagorney; Susanna R Stevens; Kenneth P Offord; Terry M Therneau; David J Plevak; Jayant A Talwalkar; W Ray Kim; Patrick S Kamath
Journal:  Gastroenterology       Date:  2007-01-25       Impact factor: 22.682

7.  Different methods of creatinine measurement significantly affect MELD scores.

Authors:  Evangelos Cholongitas; Laura Marelli; Andrew Kerry; Marco Senzolo; David W Goodier; Devaki Nair; Michael Thomas; David Patch; Andrew K Burroughs
Journal:  Liver Transpl       Date:  2007-04       Impact factor: 5.799

8.  Renal outcomes after liver transplantation in the model for end-stage liver disease era.

Authors:  Pratima Sharma; Kathy Welch; Richard Eikstadt; Jorge A Marrero; Robert J Fontana; Anna S Lok
Journal:  Liver Transpl       Date:  2009-09       Impact factor: 5.799

9.  Is waiting time a measure of access to liver transplantation? Is shorter necessarily better?

Authors:  Richard B Freeman
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

10.  Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation.

Authors:  Victor I Machicao; Titte R Srinivas; Alan W Hemming; Consuelo Soldevila-Pico; Roberto J Firpi; Alan I Reed; Giuseppi J Morelli; David R Nelson; Manal F Abdelmalek
Journal:  Liver Transpl       Date:  2006-05       Impact factor: 5.799

View more
  17 in total

1.  Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis.

Authors:  Maximilian Jara; Tomasz Dziodzio; Maciej Malinowski; Katja Lüttgert; Radoslav Nikolov; Paul Viktor Ritschl; Robert Öllinger; Johann Pratschke; Martin Stockmann
Journal:  Dig Dis Sci       Date:  2018-11-07       Impact factor: 3.199

2.  Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.

Authors:  Ying-Fen Hong; Zhan-Hong Chen; Xiao-Kun Ma; Xing Li; Dong-Hao Wu; Jie Chen; Min Dong; Li Wei; Tian-Tian Wang; Dan-Yun Ruan; Ze-Xiao Lin; Jing-Yun Wen; Qu Lin; Chang-Chang Jia; Xiang-Yuan Wu
Journal:  Tumour Biol       Date:  2015-11-11

3.  Serum levels of ferritin and transferrin serve as prognostic factors for mortality and survival in patients with end-stage liver disease: A propensity score-matched cohort study.

Authors:  Jörn Arne Meier; Arne Bokemeyer; Friederike Cordes; Valentin Fuhrmann; Hartmut Schmidt; Anna Hüsing-Kabar; Iyad Kabar
Journal:  United European Gastroenterol J       Date:  2019-11-26       Impact factor: 4.623

Review 4.  Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development.

Authors:  Sharin E Roth; Mark I Avigan; David Bourdet; David Brott; Rachel Church; Ajit Dash; Douglas Keller; Philip Sherratt; Paul B Watkins; Lucas Westcott-Baker; Silvia Lentini; Michael Merz; Lila Ramaiah; Shashi K Ramaiah; Ann Marie Stanley; John Marcinak
Journal:  Clin Pharmacol Ther       Date:  2019-09-14       Impact factor: 6.875

5.  Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases.

Authors:  K Tai; S Komatsu; K Sofue; M Kido; M Tanaka; K Kuramitsu; M Awazu; H Gon; D Tsugawa; H Yanagimoto; H Toyama; S Murakami; T Murakami; T Fukumoto
Journal:  BJS Open       Date:  2020-04-11

6.  N-myc and STAT interactor correlates with severity and prognosis in acute-on-chronic liver failure of hepatitis B virus.

Authors:  Lifu Xiong; Yanan Du; Tianhui Zhou; Bingying Du; Phimphone Visalath; Lanyi Lin; Shisan Bao; Wei Cai
Journal:  J Gastroenterol Hepatol       Date:  2019-03-07       Impact factor: 4.029

7.  Utility of Urinary Neutrophil Gelatinase Associated Lipocalin (NGAL) in Decompensated Cirrhosis.

Authors:  S Sai Krishna Reddy; Mukta Wyawahare; P S Priyamvada; Soundravally Rajendiran
Journal:  Indian J Nephrol       Date:  2019-11-11

8.  Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Zhong Wang; Yi-Fan Wu; Zhen-Dong Yue; Hong-Wei Zhao; Lei Wang; Zhen-Hua Fan; Yu Zhang; Fu-Quan Liu
Journal:  World J Gastroenterol       Date:  2021-02-07       Impact factor: 5.742

9.  Validation of a new prognostic model to predict short and medium-term survival in patients with liver cirrhosis.

Authors:  Tomasz Dziodzio; Robert Öllinger; Wenzel Schöning; Antonia Rothkäppel; Radoslav Nikolov; Andrzej Juraszek; Paul V Ritschl; Martin Stockmann; Johann Pratschke; Maximilian Jara
Journal:  BMC Gastroenterol       Date:  2020-08-12       Impact factor: 3.067

10.  End-stage liver disease score and future liver remnant volume predict post-hepatectomy liver failure in hepatocellular carcinoma.

Authors:  Fan-Hua Kong; Xiong-Ying Miao; Heng Zou; Li Xiong; Yu Wen; Bo Chen; Xi Liu; Jiang-Jiao Zhou
Journal:  World J Clin Cases       Date:  2019-11-26       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.